Cipla Partners SBP for Breast Cancer Drug in India

New Delhi, Aug 31 (PTI) Drug major Cipla on Monday said it has entered into an exclusive licensing and supply agreement with Hong Kong-based Sino Biopharmaceutical Ltd to develop and commercialise 'Rolditamig Deuderuxtecan', which is aimed at treating advanced breast cancer.

Under the agreement, Cipla will receive exclusive rights to 'Rolditamig Deuderuxtecan, or TQB2102 for India, South Africa, and five other emerging markets, the company said in a regulatory filing.

Developed by Sino Biopharmaceutical Ltd (SBP) group's subsidiary, Chia Tai Tianqing Pharmaceutical Group (CTTQ), TQB2102 is also being evaluated for different types of cancers, including breast cancer, colorectal cancer, and biliary tract cancer across multiple treatment settings.

As part of the agreement, Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.


Cipla Managing Director and Global Chief Executive Officer Achin Gupta said, "Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate."

Through the partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access across licensed territories, he added.

"Expanding global access to medicines developed by SBP Group is a central part of our strategy," said Eric Tse, CEO, SBP Group.

"TQB2102 has demonstrated encouraging clinical potential across different HER2-expressing breast cancer populations. Cipla's scale, local expertise and commitment to patient access make it a strong partner to help bring this treatment to patients across India, South Africa and other emerging markets," Tse added.